Erratum: Immunohistochemical expression of BRCA1 and lethal prostate cancer (Cancer Research (2010) 70, (3136-3139) DOI:10.1158/0008-5472.CAN-09-4100);Immunohistochemical expression of BRCA1 and lethal prostate cancer

Cancer Research

Volumn 70, Issue 8, 2010, Pages 3136-3139

  Fiorentino, Michelangelo ^a,d   Judson, Gregory ^b,c   Penney, Kathryn ^b,c   Flavin, Richard ^a   Stark, Jennifer ^b,c   Fiore, Christopher ^a   Fall, Katja ^b,c,e   Martin, Neil ^b,c   Ma, Jing ^b   Sinnott, Jennifer ^b,c   Giovannucci, Edward ^b,c   Stampfer, Meir ^b,c   Sesso, Howard D ^b,c   Kantoff, Philip W ^a,f   Finn, Stephen ^a   Loda, Massimo ^a,f   Mucci, Lorelei ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; KI 67 ANTIGEN;

ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPAIR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION;

EID: 77951069726     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1347     Document Type: Erratum

References (21)

1. Chen J, Silver DP, Walpita D, et al. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 1998;2:317-328 (Pubitemid 128379272)
2. Scully R, Chen J, Ochs RL, et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997;90:425-435 (Pubitemid 27347233)
3. Starita LM, Parvin JD. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr Opin Cell Biol 2003;15:345-350
4. 2-M cell cycle control in human mammary epithelial cells. Cancer Res 1997;57:3351-3355
5. MacLachlan TK, Somasundaram K, Sgagias M, et al. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J Biol Chem 2000;275:2777-2785 (Pubitemid 30082049)
6. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006;25:5854-5863 (Pubitemid 44453441)
7. Agalliu I, Gern R, Leanza S, Burk RD. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res 2009;15:1112-1120
8. Douglas JA, Levin AM, Zuhlke KA, et al. Common variation in the BRCA1 gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:1510-1516 (Pubitemid 47076887)
9. Mitra A, Fisher C, Foster CS, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008;98:502-507 (Pubitemid 351161242)
10. Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol 2009;3:138-150
11. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-1706
12. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:929-935 (Pubitemid 47073499)
13. Schayek H, Haugk K, Sun S, True LD, Plymate SR, Werner H. Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res 2009;15: 1558-1565
14. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009;301:52-62.
15. Hennekens CH, Eberlein K. A randomized trial of aspirin and β-carotene among U.S. physicians. Prev Med 1985;14:165-168 (Pubitemid 16203049)
16. Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008;100:815-825 (Pubitemid 351809667)
17. Stark JR, Perner S, Stampfer MJ, et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 2009;27:3459-3464
18. Müntener M, Epstein JI, Hernandez DJ, et al. Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 2008;53:767-775
19. Zellweger T, Günther S, Zlobec I, et al. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer 2009;124:2116-2123
20. Pollack A, DeSilvio M, Khor LY, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 2004;22:2133-2140 (Pubitemid 41095146)
21. Burga LN, Tung NM, Troyan SL, et al. Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Res 2009;69:1273-1278